This is basically a more potent version of keppra, 10 times more potent. It works on the KV3.1 potassium channels, so is the same target as Autifony's new drug but is in phase 3 and been tested for 8 years already, so should be out sooner and could potentially help with tinnitus.
"Sudies conducted by Prof Len Kaczmarek's group at Yale University suggest that Autifony's Kv3 modulators may help to restore the timing of firing of neurons in the auditory brainstem important for central auditory processing."
http://www.ncbi.nlm.nih.gov/pubmed/17199019
http://www.zacks.com/stock/news/156795/ucb-reports-phase-iii-data-on-epilepsy-drug-to-file-in-2015
"Sudies conducted by Prof Len Kaczmarek's group at Yale University suggest that Autifony's Kv3 modulators may help to restore the timing of firing of neurons in the auditory brainstem important for central auditory processing."
http://www.ncbi.nlm.nih.gov/pubmed/17199019
http://www.zacks.com/stock/news/156795/ucb-reports-phase-iii-data-on-epilepsy-drug-to-file-in-2015